Infliximab治疗强直性脊柱炎病人生存质量的研究

A study on survival quality of ankylosing spondylitis patients treated with Infliximab

[目的]探讨经Infliximab治疗后强直性脊柱炎病人的生存质量。[方法]在一项开放性研究中,0周、2周、6周时为病人静脉注射Infliximab,剂量为5mg/kg,以SF-3 6健康量表在给药0周、1 0周对病人进行调查。[结果]SF-36问卷8个健康概念调查和变化结果,经Wilcoxon符号秩和检验,差异有显著性(P<0.000 1)。[结论]Inflix-imab能够在短期改善强直性脊柱炎病人的生存质量。

Objective: To probe into the survival quality of ankylosing spondylitis patients undergoing Infliximab treatment.Method: A total of 55 cases of ankylosing spondylitis patients were intravenously injected Infliximab in 0 week,the 2nd and the 6th week at the dosage of 5 mg/kg in an open study.Totally 36 questions of SF-36 health scale were investigated in all cases on 0 week and 10 weeks after injection of the drug respectively.Results:In terms of 8 health concepts of SF-36 questionnaire,the survey and the changes showed a significant difference via Wilcoxon signed rank sum test(P<0.000 1).Conclusion:Infliximab could improve the survival quality of patients with ankylosing spondylitis within a short period of time.